0001)[8], with patients nearly twice as likely to remain relapse-free for more than two years compared to those receiving placebo (31%
vs. 16%, p=0.007)[8]. In addition, treatment with interferon beta-1b may slow disease progression[9]. After two years, almost three-quarters of patients who experienced a single episode of neurological disease lasting 24 hours or more did not progress to clinically definite MS[10].